Literature DB >> 8622876

Investigation of co-amplification of the candidate genes ornithine decarboxylase, ribonucleotide reductase, syndecan-1 and a DEAD box gene, DDX1, with N-myc in neuroblastoma. United Kingdom Children's Cancer Study Group.

R E George1, R M Kenyon, A G McGuckin, A J Malcolm, A D Pearson, J Lunec.   

Abstract

Although N-myc amplification is strongly associated with a poor prognosis, not all patients with neuroblastomas having N-myc amplification fare badly. To investigate whether genes other than N-myc are responsible for contributing to the prognosis, we examined seven cell lines and 87 primary tumours for co-amplification of candidate genes known to be present near the normal N-myc locus: ornithine decarboxylase (ODC), ribonucleotide reductase (RRM2), syndecan-1 and a DEAD box protein gene, DDX1. Sequence analysis of the pG21 cDNA clone previously reported to represent an expressed gene frequently co-amplified with N-myc, showed this to be from the DDX1 gene. No co-amplification with the first three genes was found in any of the cell lines or tumour samples. DDX1, however was found to be amplified along with N-myc in 4/6 (67%) cell lines and 6/16 (38%) of the N-myc amplified tumours. Co-amplification of DDX1 and N-myc was found more frequently in stage 4 or 4S tumours than lower stage (1-3) tumours. With the exclusion of a single 4S case, there was a highly significant reduction in the mean disease-free interval from 24.4 +/- 4.7 (SE, n = 10) months for cases with co-amplification of N-myc and DDX1 compared with 9.2 +/- 1.8 (SE, n = 5) months for those cases showing amplification of N-myc alone (P = 0.0056, Welch's unpaired t-test). No amplification of DDX1, ODC, RRM2, or syndecan-1 was found in the absence of N-myc amplification. These observation indicate that the N-myc amplicon is of varied size and/or position relative to the N-myc gene, with DDX1 representing at least one other gene frequently co-amplified with N-myc. Further studies are required to confirm the biological and prognostic significance of DDX1 co-amplification and to elucidate the role that DDX1 plays in tumour genesis and progression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8622876

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  Association of human DEAD box protein DDX1 with a cleavage stimulation factor involved in 3'-end processing of pre-MRNA.

Authors:  S Bléoo; X Sun; M J Hendzel; J M Rowe; M Packer; R Godbout
Journal:  Mol Biol Cell       Date:  2001-10       Impact factor: 4.138

2.  Application of comparative genomic hybridization, spectral karyotyping, and microarray analysis in the identification of subtype-specific patterns of genomic changes in rhabdomyosarcoma.

Authors:  A Pandita; M Zielenska; P Thorner; J Bayani; R Godbout; M Greenberg; J A Squire
Journal:  Neoplasia       Date:  1999-08       Impact factor: 5.715

3.  Reduced levels of DEAD-box proteins DBP-RB and p72 in fetal Down syndrome brains.

Authors:  Susanne G Kircher; Seong Hwan Kim; Michael Fountoulakis; Gert Lubec
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

Review 4.  Polyamine synthesis as a target of MYC oncogenes.

Authors:  André S Bachmann; Dirk Geerts
Journal:  J Biol Chem       Date:  2018-11-07       Impact factor: 5.157

Review 5.  The connections between neural crest development and neuroblastoma.

Authors:  Manrong Jiang; Jennifer Stanke; Jill M Lahti
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

Review 6.  The DEAD-box protein family of RNA helicases: sentinels for a myriad of cellular functions with emerging roles in tumorigenesis.

Authors:  Mohamed A M Ali
Journal:  Int J Clin Oncol       Date:  2021-03-03       Impact factor: 3.402

7.  Gene amplification in PNETs/medulloblastomas: mapping of a novel amplified gene within the MYCN amplicon.

Authors:  M C Frühwald; M S O'Dorisio; L J Rush; J L Reiter; D J Smiraglia; G Wenger; J F Costello; P S White; R Krahe; G M Brodeur; C Plass
Journal:  J Med Genet       Date:  2000-07       Impact factor: 6.318

8.  Syndecan-1 - A new piece in B-cell puzzle.

Authors:  L Kopper; A Sebestyén; M Gallai; I Kovalszky
Journal:  Pathol Oncol Res       Date:  1997-09       Impact factor: 3.201

Review 9.  c-MYC-induced genomic instability.

Authors:  Alexandra Kuzyk; Sabine Mai
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-01       Impact factor: 6.915

Review 10.  DEAD box RNA helicase functions in cancer.

Authors:  Frances V Fuller-Pace
Journal:  RNA Biol       Date:  2013-01-01       Impact factor: 4.652

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.